MCM
CRNX icon

MAI Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

MAI Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Buy
330
+115
+53% +$5.14K ﹤0.01% 3069
2025
Q4 		$10K Buy
+215
New +$9.57K ﹤0.01% 2849

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MAI Capital Management's CRNX Position: Q1 2026 in Review

MAI Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 53% in Q1 2026, buying an estimated $5.14K and bringing the position to 330 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3069.

MAI Capital Management first reported a position in CRNX in Q4 2025 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • MAI Capital Management held 330 shares of Crinetics Pharmaceuticals worth $12K as of Q1 2026.
  • MAI Capital Management bought 115 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $5.14K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3069 holding.
  • MAI Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.